Indacaterol

證據等級: L5

預測適應症: 10 個

Indacaterol: From COPD to Bronchial Disease (Asthma)

One-Sentence Summary

Indacaterol is an ultra-long-acting β₂ agonist (Ultra-LABA) with established global approval for COPD, delivering once-daily sustained bronchodilation through direct β₂ receptor activation on airway smooth muscle. The TxGNN model predicts it may be effective for Bronchial Disease (Asthma) — a closely related obstructive airway condition sharing the same pharmacological target — with 37 clinical trials and 20 publications currently supporting this direction, yielding an L1 evidence level and a recommendation to Proceed with Guardrails.

Quick Overview

Item	Content
Original Indication	COPD (Chronic Obstructive Pulmonary Disease)
Predicted New Indication	Bronchial Disease (Asthma)
TxGNN Prediction Score	99.18%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Indacaterol is an ultra-long-acting β₂-adrenoceptor agonist (Ultra-LABA) that binds selectively and with high affinity to β₂ receptors on bronchial smooth muscle. Upon binding, it activates adenylyl cyclase, elevates intracellular cAMP, and sustains smooth muscle relaxation for up to 24 hours — enabling once-daily dosing. This mechanism is direct, well-characterised, and constitutes the pharmacological foundation for its COPD indication globally.

COPD and asthma are both obstructive airway diseases driven by abnormal bronchospasm and increased airway resistance, making them mechanistically adjacent. The same β₂ receptor pathway that Indacaterol exploits in COPD is central to the management of asthmatic bronchoconstriction. While the inflammatory endotypes differ, the bronchodilatory target is identical, which explains why long-acting β₂ agonists (LABAs) are guideline-recommended backbone therapy in both conditions. This is a pharmacological bridge — not a speculative leap.

In practice, Indacaterol has already crossed this bridge. Regulatory agencies in the EU, Japan, and several other markets have approved Indacaterol-containing fixed-dose combinations for asthma maintenance: QMF149 (Atectura® Breezhaler®, IND/MF) and QVM149 (Enerzair® Breezhaler®, IND/GLY/MF). The TxGNN prediction therefore reflects a clinically validated repurposing that simply has not yet reached the Indian market.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02571777	Phase 3	Completed	3,092	52-week double-blind study comparing QVM149 (IND/GLY/MF 150/50/80 µg and 150/50/160 µg) vs QMF149 (IND/MF 150/160 µg and 150/320 µg) in poorly controlled asthma; evaluated FEV1, exacerbation rate, and asthma control
NCT02554786	Phase 3	Completed	2,216	52-week double-blind comparison of QMF149 (IND/MF 150/160 µg and 150/320 µg) vs mometasone furoate monotherapy (400 µg and 800 µg daily) in poorly controlled asthmatic patients
NCT03158311	Phase 3	Completed	1,426	24-week non-inferiority study of QVM149 vs free triple combination (salmeterol/fluticasone + tiotropium) in uncontrolled moderate-to-severe asthma
NCT00529529	Phase 3	Completed	805	26-week safety study of Indacaterol 300 µg and 600 µg once daily vs salmeterol 50 µg twice daily in patients with moderate-to-severe persistent asthma
NCT05562466	Phase 3	Recruiting	200	Double-blind crossover study evaluating QMF149 (IND/MF 150/80 µg and 150/160 µg) vs budesonide in children aged 6–11 years with asthma; completion expected May 2028
NCT05217810	N/A	Recruiting	600	24-week prospective post-marketing surveillance of Atectura® (QMF149 150/80, 150/160, 150/320 µg) under routine clinical practice conditions
NCT04656223	N/A	Completed	434	26-week real-world observational study assessing asthma control changes under MF/IND/GLY Breezhaler® with digital sensor vs fixed-dose triple therapy
NCT01609478	Phase 2	Completed	335	12-week double-blind RCT of Indacaterol acetate 75 µg and 150 µg vs placebo in persistent asthma; established efficacy and PK data supporting dose selection for QMF149
NCT02892019	Phase 2	Completed	79	Randomised active-controlled study of Indacaterol acetate 75 µg and 150 µg in pediatric asthma (6–11 years); dose-response exploration and systemic exposure comparison vs adult data
NCT00927901	Phase 2	Completed	30	Double-blind placebo-controlled 4-way crossover study comparing Indacaterol maleate, xinafoate, and acetate salts in persistent asthma; all salts demonstrated significant bronchodilation vs placebo

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32653074	2020	RCT	The Lancet. Respiratory Medicine	IRIDIUM study: once-daily MF-IND-GLY triple therapy significantly reduced moderate-to-severe exacerbations and improved FEV1 vs ICS-LABA dual therapy in inadequately controlled asthma; landmark Phase 3 evidence for Indacaterol-containing triple combination
39905183	2025	Systematic Review & Meta-analysis	Scientific Reports	Comparative efficacy of BDP/FOR/GLY vs other triple therapies (including IND-containing regimens) in uncontrolled asthma; confirms superiority of triple fixed-dose combinations over dual therapy
34783265	2022	RCT	Expert Review of Respiratory Medicine	Clinical review of IND/GLY/MF (Enerzair®) in moderate-to-severe asthma, summarising Phase 3 efficacy and safety data; supports use as step-up therapy
33871819	2021	Review	Drugs	Comprehensive appraisal of Indacaterol/Glycopyrronium/Mometasone (Enerzair® Breezhaler®); covers mechanism, Phase 3 trial evidence, and EU regulatory approval for adult asthma
33711782	2021	Safety Analysis	Respiratory Medicine	Pooled Phase 3 cardiovascular safety analysis of MF/IND and MF/IND/GLY fixed-dose combinations; no increased major adverse cardiovascular event risk observed across asthma populations
34329722	2021	PK Study	Pulmonary Pharmacology & Therapeutics	Dose-bridging data for mometasone furoate across once-daily IND/MF and IND/MF/GLY formulations; confirms regulatory dose equivalence supporting labelling decisions
32967685	2020	Clinical PK/PD	Respiratory Research	Lung function, PK, and tolerability of inhaled Indacaterol maleate vs acetate in asthma patients; both salts show comparable FEV1 improvement and tolerability profiles
31425937	2019	Review	Respiratory Medicine	Ultra-LABAs (indacaterol, olodaterol, vilanterol) in asthma: pharmacological rationale, development status, and clinical considerations for ICS co-administration
24247039	2014	Review	Current Opinion in Pulmonary Medicine	Overview of current and novel bronchodilators in asthma and COPD; positions Indacaterol within the evolving once-daily LABA landscape and identifies asthma as a target
22611179	2012	Review	Pharmacological Reviews	Landmark pharmacology review of β₂-agonists, muscarinic antagonists, and xanthines; establishes mechanistic basis for bronchodilators including Indacaterol across airway diseases

India Market Information

Indacaterol currently has no registered products in India. No marketing authorizations have been identified in the dataset.

This drug is not yet marketed in India. All clinical evidence cited above is derived from global development programmes. Regulatory filing with CDSCO would be required before any commercial use in India.

Safety Considerations

Drug Interactions (440 total interactions identified via DDInter):

The most clinically significant interactions identified are listed below. Moderate interactions are particularly relevant for patients with comorbid metabolic or cardiovascular conditions — populations who commonly have concurrent airway disease.

Interacting Drug	Level	Clinical Consideration
Epinephrine	Moderate	Additive sympathomimetic effects; concurrent use may potentiate cardiovascular stimulation (tachycardia, hypertension)
Clarithromycin	Moderate	Strong CYP3A4 inhibitor; may elevate Indacaterol plasma concentrations — monitor for β₂-related adverse effects
Metformin	Moderate	β₂ agonists may attenuate hypoglycaemic effect and cause transient hyperglycaemia; monitor blood glucose
Canagliflozin	Moderate	Potential antagonism of glucose-lowering effect; blood glucose monitoring recommended
Dapagliflozin	Moderate	Same class concern; monitor glycaemic control during co-administration
Pioglitazone	Moderate	Monitor blood glucose; beta-2 agonist-mediated glycogenolysis may affect insulin sensitivity
Saxagliptin	Moderate	Monitor glycaemic control in diabetic patients
Alogliptin	Moderate	Monitor glycaemic control in diabetic patients
Acarbose	Moderate	Potential blunting of glucose-lowering effect
Albiglutide	Moderate	Monitor for altered glycaemic response

Minor interactions were identified with inhaled corticosteroids (budesonide, beclomethasone, betamethasone, dexamethasone, triamcinolone) — these are expected co-medications in asthma management and are generally well tolerated in combination regimens.

Formal package insert warnings and contraindications were not available in this evidence pack. Please refer to the prescribing information for the relevant authorised formulation (e.g., Onbrez®, Atectura®, or Enerzair® depending on intended use) for complete safety guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Indacaterol has robust L1 evidence for bronchial disease (asthma), supported by multiple completed large Phase 3 RCTs (including IRIDIUM, NCT02571777, NCT02554786) and regulatory approvals in the EU and Japan for Indacaterol-containing fixed-dose combinations specifically for asthma maintenance. The pharmacological mechanism is directly applicable, and the COPD-to-asthma repurposing pathway is both scientifically sound and already globally validated — this is not a speculative repurposing but a documented regulatory extension yet to reach India.

To proceed, the following is needed:

Engage CDSCO on regulatory pathway for importing or licensing an already-approved Indacaterol-containing formulation (Atectura® or Enerzair®) for the Indian market
Obtain and review the full prescribing information (package insert) to document official warnings, contraindications, and labelling requirements — currently a blocking data gap
Confirm DrugBank MOA documentation to complete pharmacovigilance dossier
Develop India-specific risk management plan addressing cardiovascular monitoring (given moderate DDI with sympathomimetics) and glycaemic monitoring for diabetic co-morbidities
Consider paediatric development pathway given active Phase 3 trials in children 6–17 years
Evaluate whether to pursue Indacaterol maleate (COPD-approved salt, e.g. Onbrez®) or Indacaterol acetate (asthma-combination salts) depending on target product profile
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.